Prilenia, a clinical biotechnology company, offers a highly selective sigma-1 receptor (S1R) agonist called Pridopidine. This oral drug candidate has an established safety profile and shows potential in treating multiple movement disorders and neurodegenerative diseases affecting both adults and children. Prilenia, founded in 2018, is currently conducting a global Phase 3 trial for the treatment of Huntington's disease and a Phase 2/3 trial for ALS. Led by Dr. Michael Hayden, a renowned figure in the biotech industry, Prilenia aims to develop innovative drug products and has a strong presence in Naarden, the Netherlands, Herzliya, Israel, and Boston, MA.